Table 1.

Outcomes in patients with cancer and COVID-19

AliveDeceased
Total157 (72%)61 (28%)
Solid tumors123 (75%)41 (25%)
 Genitourinary39 (85%)7 (15%)
 Breast24 (86%)4 (14%)
 Colorectal13 (62%)8 (38%)
 Gynecologic8 (62%)5 (38%)
 Lung5 (45%)6 (55%)
 Head and neck7 (88%)1 (13%)
 Neurologic7 (88%)1 (13%)
 Upper GI5 (63%)3 (38%)
 Hepatobiliary5 (71%)2 (29%)
 Bone/soft tissue4 (80%)1 (20%)
 Neuroendocrine3 (100%)0 (0%)
 Pancreas1 (33%)2 (67%)
 Skin2 (67%)1 (33%)
Hematologic malignancies34 (63%)20 (37%)
 NHL10 (67%)5 (33%)
 MDS2 (40%)3 (60%)
 MPN5 (71%)2 (29%)
 ALL4 (100%)0 (0%)
 AML1 (100%)0 (0%)
 MM8 (62%)5 (38%)
 CML0 (0%)1 (100%)
 Hodgkin lymphoma2 (40%)3 (60%)
 CLL2 (67%)1 (33%)
Myeloid malignancy8 (57%)6 (43%)
Lymphoid malignancy26 (65%)14 (35%)
  • Abbreviation: CML, chronic myeloid leukemia.